Board Member
Phibro Animal Health Corp (PAHC)Chairman
Phibro Animal Health Corp (PAHC)Equibles does not estimate personal net worth.
Get an email with a short summary when Phibro Animal Health Corp publishes a filing, an earnings call transcript or a press release.
Get PAHC alertsJack C. Bendheim is recorded as Chairman at Phibro Animal Health Corp (PAHC) since July 1, 2026 and Board Member at Phibro Animal Health Corp (PAHC). The newest filing on record that lists Jack C. Bendheim as Board Member at Phibro Animal Health Corp (PAHC) is dated September 16, 2022. Phibro Animal Health Corp reported in an 8-K filed December 18, 2025 that Jack C. Bendheim was appointed Executive Chairman, effective July 1, 2026. Phibro Animal Health Corp reported in an 8-K filed December 18, 2025 that Jack C. Bendheim resigned as Chief Executive Officer and President, effective July 1, 2026. The proxy statement of Phibro Animal Health Corp reports total compensation of $3,609,499 for Jack C. Bendheim in fiscal 2022, including a base salary of $2,185,000. Disclosed compensation is on record for 5 fiscal years. Jack C. Bendheim has spoken on 4 earnings calls across 1 company, most recently for Phibro Animal Health Corp on May 7, 2026. Phibro Animal Health Corp is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Phibro Animal Health Corp includes Daniel (Dani) Bendheim (CEO), Gerald K. Carlson (CEO and Board Member), Carol A. Wrenn (Chairman) and 7 others.
“On the Effective Date, Mr. Jack C. Bendheim will assume a new managerial role as Executive Chairman and will continue to support strategic oversight and work closely with the executive leadership team.”
“Jack C. Bendheim, the current Chairman of the Board of Directors of the Company, Chief Executive Officer and President, will resign from his position as Chief Executive Officer and President, effective July 1, 2026”
“Net sales increased 10% to $383 million and adjusted EBITDA increased 11% to $60 million. dollars. Animal health sales increased 13% with solid demand across MFAs, nutritional specialties, and vaccines.”
“In the first quarter, we delivered 55% growth in animal health sales and an 85% increase in animal health adjusted EBITDA. Clear evidence that our strategy is working.”
“I'm pleased to report another strong quarter and a standout finish to fiscal 2025 for Far-Grow Animal Health. Our results this quarter reflected a continued momentum across the business, led once again by Animal Health, where we saw a 53% sales growth and a 47% increase in adjusted EBITDA.”
“Our first quarter had some strong positives despite the overall disappointing results. Our core animal health business grew sales at a healthy 4%, and I was especially pleased to see that some of the measures we have taken to counteract margin erosion helped the Animal Health EBITDA grow at an even faster rate of 6%.”
2026-07-01–present
Start not stated–present
Last confirmed September 16, 2022
Start not stated–2026-07-01
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member, Chairman
2026-07-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Phibro Animal Health Corp (PAHC) | Chairman of the Board, President, and Chief Executive Officer | $2,185,000 | $3,609,499 |
| 2021 | Phibro Animal Health Corp (PAHC) | Chairman of the Board, President, and Chief Executive Officer | $2,125,000 | $4,001,319 |
| 2020 | Phibro Animal Health Corp (PAHC) | Chairman of the Board, President, and Chief Executive Officer | $2,125,000 | $3,023,918 |
| 2019 | Phibro Animal Health Corp (PAHC) | Chairman of the Board, President and Chief Executive Officer | $2,065,500 | $2,721,228 |
| 2018 | Phibro Animal Health Corp (PAHC) | Chairman of the Board, President, and Chief Executive Officer | $2,065,500 | $3,410,331 |
